So sánh phương pháp

	Tiêu chuẩn chẩn đoán ROME IV cho Hội chứng ruột kích thích	Chỉ số Triệu chứng Cốt lõi của Bệnh Dạ dày Tê liệt (GCSI)	Thang đo chất lượng cuộc sống liên quan đến sức khỏe GERD
Lĩnh vực	Tiêu hóa học	Tiêu hóa học	Tiêu hóa học
Họ	Process / pipeline	Process / pipeline	Process / pipeline
Năm ra đời	2016	2003	1996
Người khởi xướng	Rome Foundation (multinational expert consensus)	Revicki, D. A., Rentz, A. M., Dubois, D., et al.	Velanovich, V., Zhang, Y., Hollis, J. B., et al.
Loại	Diagnostic Criteria	Self-report	Self-report
Công trình gốc	Mearin, F., Lacy, B. E., Chang, L., et al. (2016). Bowel disorders. Gastroenterology. Published online June 2016 by the Rome Foundation.	Revicki, D. A., Rentz, A. M., Dubois, D., Kahrilas, P., Stanghellini, V., Talley, N. J., & Tack, J. (2003). Development and validation of a patient-assessed gastroparesis symptom severity index. Alimentary Pharmacology & Therapeutics, 18(1), 141–150.	Velanovich, V., Zhang, Y., Hollis, J. B., Feldman, M. I., Sampliner, R., Guan, W., & Escamilla, C. (1996). Presenting symptoms and outcome measures in reflux esophagitis. Digestive Diseases and Sciences, 41(10), 1865–1873.
Tên gọi khác	Rome IV IBS, Rome Criteria	GCSI	GERD-HRQL, GERD-HRQoL
Liên quan	4	4	4
Tóm tắt	The Rome IV criteria are the internationally accepted diagnostic standard for irritable bowel syndrome (IBS), published in 2016 by the Rome Foundation. These criteria define IBS as recurrent abdominal pain (≥1 day per week for ≥3 months) associated with altered bowel habits, without structural or biochemical abnormalities. IBS is subtyped into four patterns—IBS-constipation predominant (IBS-C), IBS-diarrhea predominant (IBS-D), IBS-mixed (IBS-M), and IBS-unclassified (IBS-U)—based on stool consistency patterns.	The Gastroparesis Cardinal Symptom Index (GCSI) is a validated, patient-reported outcome measure specifically designed to assess symptom severity in gastroparesis. Developed by Revicki and colleagues in 2003, the GCSI captures the three cardinal symptom clusters of gastroparesis: nausea and vomiting, postprandial fullness, and early satiety, plus bloating and stomach distension. The 9-item questionnaire is responsive to treatment changes and is increasingly used in clinical trials and practice to monitor gastroparesis progression and therapy response.	The GERD Health-Related Quality of Life Scale (GERD-HRQL) is a concise, validated patient-reported outcome measure for assessing the symptomatic and functional impact of gastroesophageal reflux disease (GERD). Developed by Velanovich and colleagues in 1996, the 9-item GERD-HRQL measures heartburn frequency and severity, regurgitation, and impact on sleep and medication use. The scale is highly responsive to proton pump inhibitor (PPI) therapy and is widely used in GERD trials and clinical practice.